S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Forecast, Price & News

$5.64
-0.14 (-2.42%)
(As of 04:33 PM ET)
Compare
Today's Range
$5.47
$5.79
50-Day Range
$3.14
$6.14
52-Week Range
$2.43
$6.41
Volume
1.22 million shs
Average Volume
606,455 shs
Market Capitalization
$651.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

MiMedx Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.3% Upside
$8.25 Price Target
Short Interest
Bearish
4.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of MiMedx Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$520,081 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.08) to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

494th out of 981 stocks

Surgical & Medical Instruments Industry

49th out of 98 stocks


MDXG stock logo

About MiMedx Group (NASDAQ:MDXG) Stock

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
MiMedx Group (NASDAQ:MDXG) Trading Down 4.7%
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
MiMedx Group (NASDAQ:MDXG) Lowered to "Buy" at StockNews.com
MDXG: 1Q:22 Financial Results
H.C. Wainwright Sticks to Its Buy Rating for MiMedx Group (MDXG)
Q1 2023 MiMedx Group Inc Earnings Call
See More Headlines

MDXG Price History

MDXG Company Calendar

Last Earnings
5/02/2023
Today
6/08/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
Employees
811
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$9.50
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+45.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-30,200,000.00
Pretax Margin
-8.73%

Debt

Sales & Book Value

Annual Sales
$267.84 million
Book Value
($0.16) per share

Miscellaneous

Free Float
92,596,000
Market Cap
$654.30 million
Optionable
Optionable
Beta
1.54

Key Executives

  • Joe Capper
    Chief Executive Officer & Director
  • Ricci S. Whitlow
    Chief Operating Officer & Executive Vice President
  • Peter M. Carlson
    Chief Financial Officer
  • David H. Mason
    Chief Medical Officer
  • John R. Harper
    CTO, Senior VP-Research & Development













MDXG Stock - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price forecast for 2023?

2 brokers have issued 1-year target prices for MiMedx Group's stock. Their MDXG share price forecasts range from $7.00 to $9.50. On average, they expect the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 45.8% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2023?

MiMedx Group's stock was trading at $2.78 at the beginning of 2023. Since then, MDXG shares have increased by 103.6% and is now trading at $5.66.
View the best growth stocks for 2023 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our MDXG earnings forecast
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. The business earned $71.68 million during the quarter, compared to the consensus estimate of $63.48 million.

What ETFs hold MiMedx Group's stock?
What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.88%), State Street Corp (3.24%), Paradigm Capital Management Inc. NY (2.98%), Geode Capital Management LLC (1.90%), Richmond Brothers Inc. (1.52%) and Federated Hermes Inc. (0.82%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $5.66.

How much money does MiMedx Group make?

MiMedx Group (NASDAQ:MDXG) has a market capitalization of $654.30 million and generates $267.84 million in revenue each year. The company earns $-30,200,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does MiMedx Group have?

The company employs 811 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741.

This page (NASDAQ:MDXG) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -